
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mgc Pharmaceuticals Limited | LSE:MXC | London | Ordinary Share | AU000000MXC6 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0025 | -3.23% | 0.075 | 0.07 | 0.08 | 0.0775 | 0.07 | 0.07 | 3,377,400 | 08:26:20 |
Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
---|---|---|---|---|---|
Drug & Proprietary Stores | 4.3 | -20.8 | -0.6 | - | 3.32 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/3/2023 10:01 | Funding 01/03/2023 7:02am UK Regulatory (RNS & others) Mgc Pharmaceuticals (LSE:MXC) Historical Stock Chart From Feb 2023 to Mar 2023 Click Here for more Mgc Pharmaceuticals Charts. TIDMMXC RNS Number : 4761R MGC Pharmaceuticals Limited 01 March 2023 MGC Pharmaceuticals Ltd. Appointment of UK Lead Broker and Change of Company Secretary 01 March 2023 ASX, LSE: MXC MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities. MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture." --Ends-- | the mugger | |
22/3/2023 09:08 | Beware forward selling. Look at the many previous rns, another one is due in 2 weeks MGC Pharmaceuticals Limited US$10m Financing Agreement with Mercer Street 29/07/2022 7:00am UK Regulatory (RNS & others) Mgc Pharmaceuticals (LSE:MXC) Historical Stock Chart From Mar 2022 to Mar 2023 Click Here for more Mgc Pharmaceuticals Charts. TIDMMXC RNS Number : 2251U MGC Pharmaceuticals Limited 29 July 2022 MGC Pharmaceuticals Ltd. New US$10m Financing Agreement signed with US-based Strategic Fund and Largest Shareholder, Mercer Street Capital 29 July 2022 ASX, LSE: MXC MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce that it has entered into a new convertible securities financing agreement (Financing Agreement) with Mercer Street Global Opportunity Fund, LLC, a fund managed by Mercer Street Capital Partners, LLC, a United States-based institutional fund manager (together, "Mercer") and MGC Pharma's largest shareholder, to provide the Company with a substantial funding facility of up to a total of US$10m. This fully funds the current MGC Pharma business plan and replaces the unused amount of the convertible facility announced in September 2020[1] , providing MGC with material financing facility to be drawn on as required to execute its strategy. The first tranche of US$1.20 million will be provided to the Company upon satisfaction of the closing conditions (including lodging a cleansing statement), through the issue of 1.32M convertible notes with a face value of US$1 each to Mercer Street ( Tranche 1 Notes ). This US$10m financing facility provides MGC Pharma with access to significant capital in order to execute its business commercialisation strategy primarily, with Sciensus Rare in the UK and EU and AMC in the USA, as well as advance the regulatory approvals for the Company's proprietary products to drive revenues, assist in the rollout of the ZAM App and provide funding for the Group's general corporate expenses. The Company will continue implement significant non revenue driving cost controls, as announced in it recent June Quarter Activities Report, within the operations including the delay of non-core clinical trials, and will look to use funding under this agreement selectively to support new growth and strategic initiatives. Key Terms The key terms of the Financing Agreement are set out below: -- Convertible Securities facility of up to $US10m in total. -- The initial tranche of convertible securities issued will provide funding of US$1.2m to MGC Pharma. In addition, the company will issue 21,511,545 fully paid ordinary shares to Mercer in consideration for the provision of funding. Both issues will be made utilising MGC Pharma's existing capacity. -- Subsequent tranches of funding are available up to a value of US$8.8m within 18 months of execution of the agreement, with access to the additional funding subject to normal conditions precedent for a facility of this nature including MGC Pharma having sufficient capacity under Chapter 7 of the Listing Rules to issue the convertible notes or shareholder approval being obtained. -- For each US$1.00 of funding provided to MGC Pharma, the Company will issue Mercer Convertible Securities to the value of US$1.10. -- The value of outstanding Convertible Securities held by Mercer can: | the mugger | |
22/3/2023 07:15 | Order placed let's hope it's the start of regular ones | ![]() kenbos | |
21/3/2023 17:36 | Hopefully next (in due course) EU OTC approval, then a takeover for a nice premium. 10-20p? | ![]() sloppyjoe2 | |
21/3/2023 17:10 | Price held strong at end is good sign. FDA OTC is indeed a milestone.. Current mkt cap of 17m is paltry Big pharma could well be tempted to take this out on the cheap. | ![]() gotterdammerung | |
21/3/2023 16:49 | Good news at last. Hoping this is start of recovery. Long term holders will be rewarded. GLA | ![]() mam fach | |
21/3/2023 15:43 | Great volume since the US woke up... | ![]() sloppyjoe2 | |
21/3/2023 12:36 | This must now be on the radar of Big Pharma as a potential target for acquisition... | ![]() sloppyjoe2 | |
21/3/2023 12:33 | I tipped MXC yesterday | ![]() discofreddy | |
21/3/2023 11:13 | The cln has killed this dead dnt botht | ![]() ridingthewaves1 | |
21/3/2023 10:23 | Think this will soar when US markets open and UK brokers digest huge importence of OTC approval. Adding heavily at current low levels. | from russia with love | |
21/3/2023 09:54 | Certainly a step in right direction, otc status is a very significant development and highly desirable to any potential predator. | ![]() pillow | |
21/3/2023 09:37 | Heat ( sorry to cross thread ) but |I emailed Dave Horgan of CLON and posted his response on CLON CHAT LSE...he states all is on track with the JV in Bolivia Might well be worth a bob or two. In the meantime I am pleased with progress here at long last. Good luck with all you are doing.Ant | ![]() ant15 | |
21/3/2023 09:19 | Hope your correct again Ant 👍🏻 And mxc has more drugs in the pipeline not just a one trick pony Ps - I've printed of last DM and looking through it, sorry not been back but been hectic 🤦🤦 | ![]() heatseek77 |
Your Recent History | |||||||
Register now to watch these stocks streaming on the ADVFN Monitor.
Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Log in to ADVFN
Register Now |
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |
V: D: 20231004 16:20:10 |